600276 (600276) News
Follow 600276 (600276) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
Novo Nordisk to pay up to $2.6bn for rights to Hengrui Pharma weight-loss drug
The license agreement with China’s Hengrui is for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor NASDAQ:GIPR dual agonist, with potential for once-weekly o
GEOPOLITICS | Sep 29, 2026, 12:00 PM UTC
L
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui
Novo Nordisk OMXCOP:NOVO_B will pay $300 million upfront to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental GLP-1 pill, the Chinese drugmaker said on Tuesday.The deal gains Novo a further pot
GEOPOLITICS | Sep 29, 2026, 05:53 AM UTC
L
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
By Fabiana Negrin OchoaNovo Nordisk has signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion.The Danish drugmaker will pay China-based Hengrui $300
GEOPOLITICS | Sep 29, 2026, 05:00 AM UTC
L
China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
Jiangsu Hengrui Pharmaceuticals SSE:600276, China's largest drugmaker by market value, said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S OMXCOP:NOVO_B in a deal wort
GEOPOLITICS | Sep 29, 2026, 04:44 AM UTC
L
Novo And Hengrui Pharma Enter Exclusive License Agreement For HRS-1596
Novo Nordisk A/S OMXCOP:NOVO_B
NEWS | Sep 29, 2026, 04:44 AM UTC
L
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
Bagsværd, Denmark, 29 September 2026 — Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (G
NEWS | Sep 29, 2026, 04:38 AM UTC
L
US drugmakers turn to China for licensing deals
Merck NYSE:MRK on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.
GEOPOLITICS | Sep 28, 2026, 02:31 PM UTC
L
UBS Group AG's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Increases To 5.23%, Says HKEX
HKEX
EQUITY | Sep 25, 2026, 10:31 AM UTC
M
US considers rules preserving most pharma licensing deals with China
Sources say the US is working on rules for pharmaceutical investment in China that would likely preserve companies’ ability to strike most licensing deals for Chinese drugs.
REGULATION | Sep 18, 2026, 10:00 AM UTC
L
BlackRock's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Increases To 7.17% On Sept 10 From 6.56%, HKEX Shows
HKEX
EQUITY | Sep 15, 2026, 10:36 AM UTC
M
Jiangsu Hengrui says NMPA approves two new Hetrombopag olamine indications
Jiangsu Hengrui Pharmaceuticals Co Ltd said China’s NMPA has approved two new indications for its Hetrombopag olamine tablets. The company is listed on the SSE under 600276.
REGULATION | Sep 10, 2026, 04:20 PM UTC
M
Jiangsu Hengrui ribupatide injection marketing application accepted in China
Jiangsu Hengrui Pharmaceuticals Co Ltd said its ribupatide injection marketing application was accepted by China’s drug regulator.
GEOPOLITICS | Sep 09, 2026, 09:45 AM UTC
M
BlackRock lifts Hengrui H-shares stake to 7.21% from 5.92%
HKEX shows BlackRock increased its long position in H-shares of Jiangsu Hengrui Pharmaceuticals to 7.21% on Sep 2, up from 5.92%.
EQUITY | Sep 07, 2026, 10:25 AM UTC
L
Jiangsu Hengrui reports 0.39 CNY EPS, above expectations
Jiangsu Hengrui (600276) reported earnings per share of 0.39 CNY, compared with market expectations of 0.38 CNY.
EARNINGS | Aug 20, 2026, 12:11 AM UTC